PLoS ONE (Jan 2023)

Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique.

  • Coralie Ebring,
  • Régine Marlin,
  • Jonathan Macni,
  • Alexis Vallard,
  • Sébastien Bergerac,
  • Murielle Beaubrun-Renard,
  • Clarisse Joachim,
  • Mehdi Jean-Laurent

DOI
https://doi.org/10.1371/journal.pone.0278757
Journal volume & issue
Vol. 18, no. 3
p. e0278757

Abstract

Read online

Background and study aimsIn Martinique, about 33 new cases of endometrial cancer are diagnosed per year with a high mortality rate (world standardised rate of 4.9/100,000 versus 2.3/100,000 in mainland France). The present study aimed to determine the incidence and mortality of type I and type II endometrial cancers (ECs), their overall survival (OS) and disease-free survival (DFS) between 2012 and 2016.Patients and methodsThis retrospective observational cohort study used data from the Martinique Cancer Registry (MCR). 191 patients with corpus uterine cancer were extracted between 2012 and 2016. Patients with either endometrioid endometrial carcinoma (EEC), uterine papillary serous carcinomas (UPSC), uterine clear cell carcinomas (UCCC) or uterine carcinosarcomas (UCS) were included. All other uterine cancers were excluded.ResultsAmong the 163 included patients, 97 (60%) were type I and 66 (40%) were type II. The standardized incidence rate is 4.50/100,000 for type I vs. 2.66/100,000 for type II. Three years DFS for all types, type I and type II was 81.5% [74.2-86.9], 84.9% [75.4-91] and 76.7% [63.8-85.5] respectively. The five-years OS for all types, type I and type II was 47.0% [38.9-54.7] vs. 58.8% [47.3-68.5] vs. 22.8% [15.0-37.7] respectively.ConclusionsIn Martinique, we report a high proportion of type II ECs, which has a poor prognosis with few treatment options.